NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.

NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma. Oncol Rep. 2019 Jul 10;: Authors: Guo Q, Han N, Shi L, Yang L, Zhang X, Zhou Y, Yu S, Zhang M Abstract Glioblastoma (GBM) is the most common primary intracranial malignancy. GBM still exhibits high recurrence and mortality rates even following combined treatment with surgery, radiotherapy and chemotherapy, Therefore, the identification of novel therapeutic targets is urgent. Previous research has shown that nicotinamide phosphoribosyltransferase (NAMPT) plays a key role in cell metabolism and is closely related to the occurrence and development of many tumor types; yet, little is known concerning its relationship with GBM. Oncomine database analysis showed that the expression of NAMPT in GBM was higher than that in normal tissues; this finding was further confirmed by immunohistochemical staining of a tissue microarray. Data analysis with the R2 platform showed that patients with higher expression of NAMPT had worse prognoses than those with lower NAMPT expression. Using the GBM data in TCGA, four pathways enriched in the high NAMPT expression group were identified by gene set enrichment analysis (GSEA). NAMPT expression was knocked down in U87 and U251 GBM cells by lentiviral vectors carrying a small hairpin RNA (shRNA) targeting NAMPT. CCK‑8, colony formation, wound healing, Transwell and apoptosis assays were carried out. The results showed ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research